FY18 guidance is new though (hence why it was marked market sensitive). It implies good organic growth if you believe it. Also note that all things being equal NPAT will grow faster than the 10-15% Revenue growth indicated (especially if they are able to reduce debt over that period which they should in the absence of any further acquisition).
Gives you FY18 eps of 10-11cps (PE less than 8x) for a company growing at a pretty decent clip. What more do you want?
Their guidance history has been a bit up and down but generally ok - especially last years full year result when they beat revenue guidance by quite a lot.
RXP Price at posting:
79.0¢ Sentiment: Buy Disclosure: Held